Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

CARBIDOPA; LEVODOPA

CARBIDOPA;LEVODOPA

Standard Dose
36.25MG;145MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview CARBIDOPA; LEVODOPA is listed in Drugs@FDA under application 208895 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient CARBIDOPA;LEVODOPA Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 36.25MG;145MG Sponsor SANDOZ INC Submission history Latest submission status date: 2023-03-31 00:00:00.

Structured Monograph

Clinical summary

Approval overview CARBIDOPA; LEVODOPA is listed in Drugs@FDA under application 208895 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient CARBIDOPA;LEVODOPA Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 36.25MG;145MG Sponsor SANDOZ INC Submission history Latest submission status date: 2023-03-31 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.